Identification of amino acid residues important for ligand binding to Fas

Journal of Experimental Medicine

Volumn 185, Issue 8, 1997, Pages 1487-1492

  Starling, Gary C ^a   Bajorath, Jürgen ^a   Emswiler, John ^a   Ledbetter, Jeffrey A ^a   Aruffo, Alejandro ^a   Kiener, Peter A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; FAS ANTIGEN; HYBRID PROTEIN; SERINE; TUMOR NECROSIS FACTOR RECEPTOR;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL DEATH; DIAGNOSIS; ETIOLOGY; HUMAN; IMMUNE RESPONSE; LIGAND BINDING; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

ANTIGENS, CD95; BINDING SITES; CELL LINE; FAS LIGAND PROTEIN; HUMANS; MACROMOLECULAR SUBSTANCES; MEMBRANE GLYCOPROTEINS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PROTEIN BINDING; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031003088     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.185.8.1487     Document Type: Article

References (24)

1. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science (Wash. DC). 267:1449-1456.
2. Watanabe-Fukunaga, R., C.I. Brannan, N.G. Copeland, N.A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature (Lond.). 356:314-317.
3. Takahashi, T., M. Tanaka, C.I. Brannan, N.A. Jenkins, N.G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:969-976.
4. Drappa, J., A.K. Vaishnaw, K.E. Sullivan, J.-L. Chu, and K.B. Elkon. 1996. Fas gene mutations in the Canale - Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 335:1643-1649.
5. Kayagaki, N., A. Kawasaki, T. Ebata, H. Ohmoto, S. Ikeda, S. Inoue, K. Yoshino, K. Okumura, and H. Yagita. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1777-1783.
6. Ogasawara, J., R. Watanabe-Fukunaga, M. Adachi, A. Matsuzawa, T. Kasugai, Y. Kitamura, N. Itoh, T. Suda, and S. Nagata. 1993. Lethal effect of the anti-Fas antibody in mice. Nature (Lond.). 364:806-809.
7. Galle, P.R., W.J. Hofmann, H. Wjlczak, H. Schaller, G. Otto, W. Stremmel, P.H. Krammer, and L. Runkel. 1995. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182:1223-1230.
8. Dowling, P., G. Shang, S. Raval, J. Menonna, S. Cook, and W. Husar. 1996. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 184:1513-1518.
9. Liles, W.C., P.A. Kiener, J.A. Ledbetter, A. Aruffo, and S.J. Klebanoff. 1996. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med. 184: 429-440.
10. O'Connell, J., G.C. O'Sullivan, J.K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184: 1075-1082.
11. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard et al. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science (Wash. DC). 274:1363-1366.
12. Nagata, S. 1996. Apoptosis: telling cells their time is up. Curr. Biol. 6:1241-1243.
13. Huang, B., M. Eberstadt, E.T. Olejniczak, R.P. Meadows, and S.W. Fesik. 1996. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature (Lond.). 384:638-641.
14. Bajorath, J., and A. Aruffo. 1997. Prediction of the three-dimensional structure of the human Fas receptor by comparative molecular modeling. J. Computer-Aided Mol. Design. 11: 3-8.
15. Banner, D.W., A. D'Arcy, W. Janes, R. Gentz, H.-J. Schoenfeld, C. Broger, H. Loetscher, and W. Lesslauer. 1993. Crystal structure of the soluble human 55 kd TNF receptor - human TNFβ complex: implications for TNF receptor activation. Cell. 73:431-445.
16. Bajorath, J., N.J. Chalupny, J.S. Marken, A.W. Siadak, J. Skonier, M. Gordon, D. Hollenbaugh, R.J. Noelle, H.D. Ochs, and A. Aruffo. 1995. Identification of residues on CD40 and its ligand which are critical for the receptor - ligand interaction. Biochemistry. 34:1833-1840.
17. Bajorath, J., J.S. Marken, N.J. Chalupny, T.L. Spoon, A.W. Siadak, M. Gordon, R.J. Noelle, D. Hollenbaugh, and A. Aruffo. 1995. Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis. Biochemistry. 34: 9884-9892.
18. Hollenbaugh, D., L.S. Grosmaire, C.D. Kullas, N.J. Chalupny, S. Braesch-Andersen, R.J. Noelle, I. Stamenkovic, J.A. Ledbetter, and A. Aruffo. 1992. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO (Eur. Mol. Biol. Organ.) J. 11:4313-4321.
19. Malik, N., B.W. Greenfield, A.F. Wahl, and P.A. Kiener. 1996. Activation of human monocytes through CD40 induces matrix metalloproteinases. J. Immunol. 156:3952-3960.
20. Hollenbaugh, D., J. Douthwright, V. McDonald, and A. Aruffo. 1995. Cleavable CD40Ig fusion proteins and the binding to sgp39. J. Immunol. Methods 188:1-7.
21. Whitney, G.S., G.C. Starling, M.A. Bowen, B. Modrell, A.W. Siadak, and A. Aruffo. 1995. The membrane-proximal scavenger receptor cysteine rich domain of CD6 contains the activated leukocyte cell adhesion molecule binding site. J. Biol. Chem. 270:18187-18190.
22. Marsters, S.A., A.D. Frutkin, N.J. Simpson, B.M. Fendly, and A. Ashkenazi. 1992. Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding. J. Biol. Chem. 267:5747-5750.
23. Armitage, R.J., T.A. Sato, B.M. Macduff, K.N. Clifford, A.R. Alpert, C.A. Smith, and W.C. Fanslow. 1992. Identification of a source of biologically active CD40 ligand. Eur. J. Immunol. 22:2071-2076.
24. Alderson, M.R., C.A. Smith, T.W. Tough, T. Davis-Smith, R.J. Armitage, B. Falk, E. Roux, E. Baker, G.R. Sutherland, W.S. Din et al. 1994. Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 24: 2219-2227.